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th ICHNO Conference International Conference on innovative approaches in Head and Neck Oncology 14 -16 March 2019 Barcelona, Spain __________________________________________________________________________________________ radiation induced brachial plexopathy; a non-reversible late toxicity experienced by a small number of patients. The BP was analysed at the superior and inferior divisions to establish if segmental interfractional BP movement should be considered when planning radiotherapy in this high-dose region.
Material and Methods
A retrospective single centre analysis of 15 patients with head & neck cancer treated with radical bilateral neck irradiation. The extent of BP movement relative to the planning scan was assessed using weekly cone beam CT (CBCT) scans. The BP was contoured on the planning scan and the subsequent 6, weekly CBCT's; this was used to calculate the jacquard conformity index (JCI) for the left/ right and superior/inferior divisions of the BP.
Results
The mean JCI for right and left superior BP was 44.4±15.5% whereas the mean JCI for right & left inferior BP was 38.3±15.5%. There was a statistically significant difference between superior and inferior JCI p=0.0002 95% CI (-9.26 to -2.88). Bilateral superior BP JCI was higher, with better conformity than the corresponding inferior divisions.
Conclusion
Interfractional BP movement occurs; the greatest movement is seen at the inferior division. This data suggests re-evaluating current BP margins and consideration of a larger inferior BP PRV margin. 
PO-056

Purpose or Objective
Management of the N3 Neck following radical chemoradiation (CRT) for head and neck cancer (HNC) remains unclear. Published studies to date report on small numbers of patients with N3 disease. We investigated the use of post-treatment imaging to direct management of the N3 neck in this setting.
Material and Methods
We retrospectively reviewed consecutive patients with HNC and N3 neck nodal disease treated with CRT. All patients were assessed at 12-16 weeks post-CRT with CT or PET-CT scan. Patients with residual disease on imaging were treated with selective neck dissection (SND).
Results
Between 01/2012 and 12/2017, 19 patients (17 (89.5%) males) with Tx-T4N3M0 HNC were treated. Eleven (57.9%) patients had p16+ve disease. Fifteen (78.9%) patients received CRT and 4 (21.1%) patients were treated with radiotherapy alone. Median (range) follow up was 25.5 (3-51) months. Three p16+ve patients (15.8%) had SND for residual disease post-CRT: 2 patients had confirmed residual disease on histology. Fifteen (78.9%) patients were assessed with PET-CT: 8 (53.3%) patients had no residual disease or activity and remain in remission without SND. Of the 7 (46.7%) patients with residual disease or activity on imaging, 5 patients were managed with surveillance (2 patients in remission, 3 cancerrelated deaths) and 2 patients were treated with SND (both were positive for residual disease) and remain in remission. Five (45.5%) p16+ve patients had residual disease post-treatment: one had metastatic disease, 2 had SND with residual disease on histology, 1 had SND with no residual disease on histology, and 1 patient remained in remission without SND and died at 50 months of noncancer-related causes. None of the 8 p16-ve patients had SND: 2 (25%) had no residual disease and remain in remission, 6 (75%) developed residual or metastatic disease post-treatment. Two-year disease-free survival and overall survival was 37.5% and 75% for p16-ve patients, respectively, and 90.9% and 90.9%, respectively, for p16+ve patients.
Conclusion
Patients with p16+ve HNC and N3 nodal disease have better response to CRT and overall survival than p16-ve HNC. Surveillance for patients with none or only structural residual disease on post-CRT imaging is reasonable, particularly for p16+ve disease. Analysis of pooled data from published studies will help to inform management of the neck in this setting. 
PO-057 Predicting risk of Acute
Purpose or Objective
Head and neck (HN) cancer patients treated with concurrent radiotherapy with cisplatin (CTRT) are at -risk of acute kidney injury (AKI). AKI often requires in-patient management with implications for healthcare resources and patients' quality of life. We sought to identify pretreatment risk factors for development of AKI to inform clinical management of this group.
Material and Methods
A retrospective analysis was conducted of HN patients receiving curative volumetric modulated arc radiotherapy (VMAT) with cisplatin (100mg/m2 week 1 and 4), between February 2016 and May 2017 at our institution. Patients were generally required to have an isotope Glomerular Filtration Rate (GFR) > 60ml/min pre-treatment. Demographic, clinical and dosimetric parameters were collected. All episodes of AKI (defined as a rise of ≥ 26 µmol/l in serum creatinine level or 1.5 x baseline) during treatment were identified. Logistic regression was employed to investigate the associations between risk of AKI and parameters listed in Table 1 . Multivariate logistic regression model, using stepwise backward selection, was conducted for parameters having p < 0.05 in the univariate analysis or felt clinically likely to be related to AKI risk. 2-tailed p-values less than 0.05 were considered as significant. Results 133 patients were identified. All were treated to 60-66 Gy. 39% (35) developed AKI during treatment and 11 % (15) of these had a persistent rise in serum creatinine from baseline of > 20 at last review. Factors significant on univariate analysis for AKI are shown in table 1. On multivariate analysis increasing age and use of ACEInhibitors (ACE-I) or Angiotensin Receptor Blockers (ARB) were associated with an increased risk of AKI. Careful management is required to minimise its incidence. Consideration should be given to stopping ACE-I/ARB medications when safe to do so prior to treatment. Older patients are at increased risk of AKI and may benefit from more frequent monitoring of serum creatinine during therapy to ensure adequate hydration is maintained. It is not possible to predict risk based on disease characteristics or baseline renal function, consistent with previously published findings for patients receiving cisplatin chemotherapy. . Estimated 1-year OS was 66.2%; 2-year was 45% and 5-year was 28.6%. Conclusion Conclusion: Induction chemotherapy with TPF provided a survival benefit to the locally advanced head and neck cancer. Even though the adverse effects appeared in a significant percentage of cases, these are easily handle with support therapeutics and doses adjustment, and the number of complete responses and the long survivals in this type of cancer is encouraging. Our study assume an importance because of this is a real-life population, which highlights the TPF benefit. 
PO-058
PO-059
Purpose or Objective
To determine whether some major nutritional parameters, namely Body mass index (BMI), serum
